BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Reports Up to 83% Accuracy in AI Intoxication Detection Testing, Announces $350,000 Private Placement
This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced that its artificial intelligence ("AI")-driven voice analytics technology is nearing final product testing ahead of its first commercial pilot, with intoxication detection accuracy reaching up to 83% under certain testing conditions. The company reported that its prediction models, tested with and without sober baseline tracking, have exceeded the accuracy of some commercially available cheek swab tests. MindBio plans to conduct additional human testing over the next two to three weeks before launching its first commercial…











